Exp Clin Endocrinol Diabetes 2000; Vol. 108(4): 265-274
DOI: 10.1055/s-2000-7754
Articles

© Johann Ambrosius Barth

How asymptomatic is asymptomatic primary hyperparathyroidism?

C. Hasse 1 , H. Sitter 2 , S. Bachmann 3 , A. Zielke 1 , M. Koller 2 , C. Nies 1 , W. Lorenz 2 , M. Rothmund 1
  • 1 Department of Surgery, Philipps-University of Marburg, Germany
  • 2 Institute of Theoretical Surgery, Philipps-University of Marburg, Germany
  • 3 Department of Surgery, Stadtkrankenhaus Korbach, Germany
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Summary:

We observed several cases of patients who believed they were free of symptoms or signs of primary hyperparathyroidism (pHPT) preoperatively, reported a change of complaints following parathyroidectomy (PTX). We, therefore, decided to examine a larger group of patients to discover if these findings were incidental or of more general significance. The role of PTX in these patients with asymptomatic pHPT remains controversial. In 1991 criteria were defined at a NIH-consensus conference, according to which patients qualify for either operative therapy or long term medical surveillance. Until now, it was generally believed that the majority of asymptomatic patients would never develop symptoms.

In a epidemiological cohort-study, the perioperative data of 582 consecutive patients with pHPT, including 116 asymptomatic patients (20.9%), who underwent parathyroidectomy between 1987 and 1998 were evaluated by uni- and multivariate analysis. At a median of 72 months postoperatively, all patients underwent a planned follow-up which included a standardised, validated questionnaire, physical examination and laboratory investigations.

Eighty-six patients who were asymptomatic preoperatively were available for follow-up. Only eight (9.3%) were definitely asymptomatic, 4.6% of the entire, representative cohort. Postoperative improvement was reported in 81.4% of the “asymptomatic” patients. Multivariate analysis did not reveal a single or a set of preoperative measurements, that would allow to predict the retrospectively definitely asymptomatic patient. PTX resulted in normocalcaemia in 98.8% of preoperatively asymptomatic patients, with an operative morbidity of 1.2% and no mortality.

Many apparently asymptomatic patients with pHPT will only realise that they did in fact have preoperative symptoms in retrospect, following PTX. This study suggests that using an up-to-date definition of asymptomatic pHPT, there are only a small number of truly asymptomatic patients and that these cannot be predicted preoperatively, as their symptoms may become apparent only after PTX. “Asymptomatic” patients with pHPT may share the same objective and subjective benefits from PTX as symptomatic patients. They should be operated as soon as the diagnosis is established.

References

  • 1 Anonymous . Consensus development conference statement.  J Bone Mineral Res. 6 9-13 1991; 
  • 2 Auerbach G A, Marx S J, Spiegel A M. Parathyroid hormone, calcitonin and the calciferols. In: Wilson JD, Foster DW (eds) Williams textbook of endocrinology vol 8: pp 1431-1432 Saunders, Philadelphia, London, Toronto 1991
  • 3 Bilezikian J P, Silverberg S J, Shane E, Parisien M, Dempster D W. Characterization and evaluation of asymptomatic primary hyperparathyroidism.  J Bone Mineral Res. 6 85-124 1991; 
  • 4 Brazier J E, Harper R, Jones N M, O'Cathain A, Thomas K J, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care.  BMJ. 305 160-164 1992; 
  • 5 Breetvelt I S, van Dam F SAM. Underreporting by cancer patients: The case of response-shift.  Soc Sci Med. 32 981-987 1991; 
  • 6 Burney R E, Jones K R, Christy B, Thompson N W. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels.  Surgery. 125 608-614 1999; 
  • 7 Burney R E, Jones K R, Coon J W, Blewitt D K, Herm A M. Assessment of patient outcomes after operation for primary hyperparathyroidism.  Surgery. 120 1013-1019 1996; 
  • 8 Chan A K, Duh Q Y, Katz M H, Siperstein A E, Clark O H. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy.  Ann Surg. 222 402-413 1995; 
  • 9 Chou F-F, Sheen-Chen S-M, Leong C-P. Neuromuscular recovery after parathyreoidectomy in primary hyperparathyroidism.  Surgery. 117 18-25 1995; 
  • 10 Christensson T, Hellstrom K, Wengle B, Alveryd A, Wikland B. Prevalence of hypercalcaemia in a health screening in Stockholm.  Acta Med Scand. 200 131-137 1976; 
  • 11 Clark O H, Wilkes W, Siperstein A E, Duh Q Y. Diagnosis and management of asymptomatic hyperparathyroidism: Safety, efficacy, and deficiencies in our knowledge.  J Bone Mineral Res. 6 135-142 and 151-152 1991; 
  • 12 Clark O H. Presidential address: “Asymptomatic” primary hyperparathyroidism: Is parathyroidectomy indicated?.  Surgery. 116 947-953 1994; 
  • 13 Fitzpatrick L A, Bilezikian J P. Primary hyperparathyroidism. In: Becker KL (ed) Principles and practice of endocrinology and metabolism vol 1: pp 431-433 Lippincott, Grand Rapids, New York, St. Louis, San Francisco, London, Sydney, Tokyo 1990
  • 14 Habener J, Arnold A, Potts J T. Hyperparathyroidism. In: DeGroot LJ (ed) Endocrinology vol 2: pp 1048-1055 Saunders, Philadelphia, London, Toronto 1995
  • 15 Harrison B J, Wheeler M H. Asymptomatic primary hyperparathyroidism.  World J Surg. 15 724-729 1991; 
  • 16 Heath H, Hodgson S F, Kennedy M A. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community.  New Engl J Med. 302 189-193 1980; 
  • 17 Heath H. III. Clinical spectrum of primary hyperparathyroidism: Evolution with changes in medical practice and technology.  J Bone Mineral Res. 6 63-70 1991; 
  • 18 Hedbäck G, Oden A, Tisell L-E. The influence of surgery on the risk of death in patients with primary hyperparathyroidism.  World J Surg. 15 399-407 1991; 
  • 19 Hedbäck G, Tisell L-E, Bengtsson B-A, Hedman I, Oden A. Premature death in patients operated on for primary hyperparathyroidism.  World J Surg. 14 829-836 1990; 
  • 20 Joborn C, Hetta J, Lind L, Rastad J, Akerström G, Ljunghall S. Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with long-standing mild hypercalcemia.  Surgery. 105 72-78 1989; 
  • 21 Kaplan E L, Yashiro T, Salti G. Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease.  Ann Surg. 215 300-317 1992; 
  • 22 Kjellman M, Sandelin K, Farnebo L O. Primary hyperparathyroidism. Low surgical morbidity supports liberal attitude to operation.  Arch Surg. 129 237-240 1994; 
  • 23 Lundgren E, Reastad J, Ridefelt P, Juhlin C, Akerström G, Ljunghall S. Long-term effects of parathyroid operation on serum calcium and parathyroid hormone values in sporadic primary hyperparathyroidism.  Surgery. 112 1123-1129 1992; 
  • 24 Melliere S, Berrahal D, Perlemuter L, Hindie E, Simon D. Primary hyperparathyroidism. Relationships of symptoms to age, sex, calcemia, anatomical lesions and weight of glands.  Presse Med. 24 1889-1893 1995; 
  • 25 Melton L J. Epidemiology of primary hyperparathyroidism.  J Bone Mineral Res. 6 25-32 1991; 
  • 26 Palmer M, Bergstrom R, Akerstrom G, Adami H-O, Jakobsson S, Ljunghall S. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 jears of follow-up.  Lancet. 10 59-62 1987; 
  • 27 Palmer M, Jakobsson S, Akerstrom G, Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values.  Eur J Clin Invest. 18 39-46 1988; 
  • 28 Parfitt A M, Rao D S, Kleerekoper M. Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and consideration bearing on the need for surgical intervention.  J Bone Mineral Res. 6 97-124 1991; 
  • 29 Pasieka J L, Parsons L L. Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism.  World J Surg. 22 513-519 1998; 
  • 30 Pennebaker J. The psychology of physical symptoms. vol 5: pp 1-197 Springer, New York 1982
  • 31 Ronni-Sivula H. Cause of death in patients previously operated on for primary hyperparathyroidism.  Ann Chir Gynaecol. 74 13-18 1985; 
  • 32 Silverberg S J, Bilezikian J P, Bone H G, Talpos G B, Horwitz M J, Stewart A F. Therapeutic controversies in primary hyperparathyroidism.  J Clin Endocrinol & Metab. 84 2275-2285 1999; 
  • 33 Silverberg S J, Gartenberg F, Jacobs T P, Shane E, Siris E, Staron R B, Bilezikian J P. Longitudinal measurement of bone density and biochemical indices in untreated primary hyperparathyroidism.  J Clin Endocrinol Metab. 80 723-728 1995; 
  • 34 Silverberg S J, Shane E, Jacobs T P, Siris E, Bilezikian J P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.  N Engl J Med. 341 1249-1255 1999; 
  • 35 Sivula A, Pelkonen R. Long term health risk of primary hyperparathyroidism: the effect of surgery.  Ann Med. 28 95-100 1996; 
  • 36 Solomon B L, Schaaf M, Smallridge R C. Psychologic symptoms before and after parathyroid surgery.  Am J Med. 96 101-107 1994; 
  • 37 Sosa J A, Powe N R, Levine M A, Udelsman R, Zeiger M A. Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons.  J Clin Endocrinol Metab. 83 2658-2665 1998; 
  • 38 Uden P, Chan A K, Duh Q Y, Siperstein A E, Clark O H. Primary hyperparathyroidism in younger and older patients: Clinical symptoms and outcome of surgery.  World J Surg. 16 791-797 1992; 
  • 39 Ware J J, Sherbourne C D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.  Medical Care. 30 473-483 1992; 

C. HasseMD, PhD 

Department of Surgery

Philipps-University

Baldingerstraße

D-35033 Marburg

Phone: +49-64 21-2 86 25 72

Fax: +49-64 21-2 86 89 95

Email: sitter@mailer.uni-marburg.de

    >